← all works
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Lung Cancer Treatments and Mutations
- Field
- Medicine
- Canadian institutions
- McGill University
- Funders
- Boehringer Ingelheim
- Keywords
- MedicineAfatinibPemetrexedLung cancerInternal medicineAdenocarcinomaLungGemcitabineChemotherapyPopulationGastroenterologyOncologyCisplatinSurgeryGefitinibEpidermal growth factor receptorCancer
- Has abstract in OpenAlex
- no